Dicerna Pharmaceuticals, Inc.
WATERTOWN, MA · Founded 2006 · CIK 0001399529 · Biotech · Acquired
Lipid nanoparticle-encapsulated RNAi therapeutic targeting beta-catenin for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and colorectal cancer
dicerna.com →- Grants
- $3.2M
- 3 awards
- Sector median: 1
- Raised
- $90M
- 3 Form D · Aug 2013
- 158 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 21 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020112012201320142015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $24,800,628 | |
| Private capital raised | Form D · SEC | $59,999,937 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of a clinical stage nanoparticle drug delivery platform | $184,129 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of a clinical stage nanoparticle drug delivery platform | $1,998,609 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of a clinical stage nanoparticle drug delivery platform | $998,609 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2282 | Ensysce Biosciences, Inc. | — | $103M |
| 2283 | VIACYTE, INC. | — | $150M |
| 2284 | EMULATE THERAPEUTICS, INC. | — | $12M |
| 2285 | Dicerna Pharmaceuticals, Inc. | — | $90M |
| 2286 | CytoDyn Inc. | — | $88M |
| 2287 | Geneoscopy, Inc. | — | $58M |
| 2288 | MarvelBiome, Inc. | — | $55M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Douglas FambroughDirector · Executive Officer
- Brian HalakDirector
- Stephen HoffmanDirector
- James JensonDirector
- Peter KolchinskyDirector
- Dennis LangerDirector
- Jonathan MacQuittyDirector
- David MaddenDirector · Executive Officer
Patents
- Compositions And Methods For Inhibiting Snca Expressionapplication
- Compositions And Methods For Inhibiting ANGPTL3 Expressiongranted
- Compositions And Methods For Modulating Scap Activitygranted
- Compositions And Methods For Inhibiting Mapt Expressionapplication
- Methods For Treating Hepatitis B Infectionapplication
- Compositions And Methods For Inhibiting Lpa Expressionapplication
- Methods For Treating Hepatitis B Infectiongranted
- Double-stranded Nucleic Acid Inhibitor Molecules With Shortened Sense Strandsgranted
- Ligand-Modified Oligonucleotidesapplication
- Methods For Synthesis Of PERACETYLGALACTOSAMINE-1-PENTANOIC Acidapplication
- Compositions And Methods For Inhibiting Lpa Expressiongranted
- Compositions And Methods For Modulating APOC3 Expressionapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.